REDX
PHARMA PLC
("Redx"
or the "Company")
Result of Annual General
Meeting
Alderley Park, UK, 14 March 2024 Redx (AIM:REDX), the clinical-stage biotechnology company
focused on discovering and developing novel, small molecule,
targeted therapeutics for the treatment of fibrotic disease and
cancer today announces that its Annual
General Meeting was held at 11am on 14 March 2024, with all
resolutions passed by substantial majorities.
The table below sets out the details
of the votes put to shareholders:
|
Resolution number
|
Resolution name
|
Number of
votes for & discretionary
|
% of votes
for & discretionary
|
Number of
votes against
|
% of votes
against
|
% of votes
withheld*
|
Total votes cast (including
withheld)
|
|
1
|
Receive the Company's annual
accounts
|
351,887,218
|
94.48%
|
20,551,504
|
5.52%
|
0.00%
|
372,438,722
|
|
2
|
Re-appoint Ernst & Young as
auditors
|
372,434,833
|
100.00%
|
2,586
|
0.00%
|
0.00%
|
372,438,722
|
|
3
|
Elect Dr Joseph Anderson as a
director
|
372,408,267
|
99.99%
|
3,889
|
0.00%
|
0.01%
|
372,438,722
|
|
4
|
Re-elect Dr Jane Griffiths as a
director
|
372,407,145
|
99.99%
|
5,011
|
0.00%
|
0.01%
|
372,438,722
|
|
5
|
Re-elect Peter Presland as a
director
|
351,851,226
|
94.47%
|
20,558,505
|
5.52%
|
0.01%
|
372,438,722
|
|
6
|
Re-elect Dr Robert Scott as a
director
|
351,854,954
|
94.47%
|
20,557,202
|
5.52%
|
0.01%
|
372,438,722
|
|
7
|
Authorise the directors to allot
shares
|
372,396,854
|
99.99%
|
41,868
|
0.01%
|
0.00%
|
372,438,722
|
|
8
|
Disapply pre-emption
rights
|
372,266,621
|
99.96%
|
164,843
|
0.04%
|
0.00%
|
372,438,722
|
*A
vote withheld is not a vote in law and is not counted in the
calculation of the proportion of votes 'For' or
'Against'
|
For
further information, please contact:
|
|
|
|
|
|
|
|
|
|
Redx Pharma Plc
UK
Headquarters
Caitlin Pearson, Head of
Communications
ir@redxpharma.com
|
T: +44 (0)1625 469 918
|
|
|
SPARK Advisory Partners (Nominated Adviser)
|
T: +44 (0)203 368 3550
|
|
|
Matt Davis/ Adam Dawes
|
|
|
|
|
|
|
|
WG
Partners LLP (Joint Broker)
|
T: +44 (0)203 705 9330
|
|
|
Claes Spång/ Satheesh Nadarajah/
David Wilson
|
|
|
|
|
|
|
|
Panmure Gordon (UK) Limited (Joint Broker)
|
T: +44 (0)207 886 2500
|
|
|
Rupert Dearden/ Freddy Crossley/
Emma Earl
|
|
|
|
|
|
|
|
FTI
Consulting
|
T: +44 (0)203 727 1000
|
|
|
Simon Conway/ Ciara
Martin
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
About Redx Pharma Plc
Redx Pharma (AIM: REDX) is a
clinical-stage biotechnology company focused on the discovery and
development of novel, small molecule, targeted therapeutics for the
treatment of fibrotic disease, cancer and the emerging area of
cancer-associated fibrosis. Redx aims to progress its programmes to
clinical proof of concept before evaluating options for further
development and potential value creation. The Company's lead
fibrosis product candidate, the selective ROCK2 inhibitor,
zelasudil (RXC007), is in development for interstitial lung disease
and is undergoing a Phase 2a trial for idiopathic pulmonary
fibrosis (IPF) with topline data expected in H1 2024. The Company's
second fibrosis candidate, RXC008, a
GI-targeted ROCK inhibitor for the treatment of fibrostenotic
Crohn's disease, is in Phase 1 development with healthy volunteer
data expected by the end of 2024. Redx's lead oncology product
candidate, the Porcupine inhibitor zamaporvint (RXC004), being
developed as a targeted treatment for Wnt-ligand dependent cancers,
is expected to report anti-PD-1 combination Phase 2 data during the
first half of 2024, following which Redx will seek a partner for
ongoing development.
The Company has a strong track
record of discovering new drug candidates through its core
strengths in medicinal chemistry and translational science,
enabling the Company to discover and develop differentiated
therapeutics against biologically or clinically validated targets.
The Company's accomplishments are evidenced not only by its
wholly-owned clinical-stage product candidates and discovery
pipeline, but also by its strategic transactions, which includes
the sale of pirtobrutinib (RXC005, LOXO-305), the only non-covalent
or reversible BTK inhibitor now approved by the US FDA, and
transactions with both AstraZeneca and Jazz
Pharmaceuticals.
To subscribe to Email Alerts from
Redx, please visit: www.redxpharma.com/investor-centre/email-alerts/.
